Sleep-Wake Disorders

FDA approves Takeda’s Orzeyful, first orexin agonist, improving wakefulness and reducing cataplexy in adults with narcolepsy type 1 in pivotal trials.

New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.

FDA accepts AXS-12 NDA for cataplexy in narcolepsy after phase 3 shows fewer attacks, better wakefulness, and cognition; decision due May 2027.

Check out new phase 2 dose-ranging study data evaluating alixorexton in patients with narcolepsy type 2.

REFRESH data show once-nightly sodium oxybate real-world outcomes.

REFRESH real-world study follows once-nightly sodium oxybate in narcolepsy.

Midlife sleep trouble predicts poorer well-being 9 years later, especially for women. Here's why clinicians should ask about sleep and menopause triggers.

Long-term study links sleep problems to poorer well-being in aging adults, highlighting sex differences and why insomnia isn’t just aging.

New phase 3 data show oveporexton (TAK-861) boosts functioning and cognition, eases NT1 symptoms, and improves sleep

New SLEEP 2026 insights reveal how REM sleep preserves memories while stripping emotional sting—key clues for PTSD and healthier sleep.

Behavioral therapies: important parts of sleep disorder treatment.

Menopause-related sleep disruptions and slow-wave scoring bias may skew women’s neurodegeneration risk insights, SLEEP 2026 highlights.

Explore how digital reminders boost prospective memory in aging and dementia, plus practical sleep habits that turn health knowledge into real behavior changes.

Learn more about the bidirectional relationship between sleep and waking behaviors.

Learn why awakenings are normal, sleep needs shift with age, and deep sleep protects brain health and cognition.